Olprinone HCl

Product Description

Oplinone hydrochloride selectively blocks the specific phosphodiesterase (PDE) of cyclic adenosine and has the effect of enhancing cardiac contractility and vasodilation. Oplinone hydrochloride began research in 1982 and clinical trials began in 1986, proving effective in acute heart failure. Clinical trials have also proved that oplinone hydrochloride does not increase myocardial oxygen consumption, but increases cardiac output, which is more effective than catecholamine preparations for improving myocardial energy.

Function

Oplinone hydrochloride injection expands blood vessels by selectively inhibiting myocardial and vascular smooth muscle cAMP-specific phosphodilipase isoenzyme III, thereby increasing myocardial contractility and increasing cardiac blood output, while having a direct relaxing effect on vascular smooth muscle, which has the effect of reducing pulmonary artery impedulation and reducing circulatory vascular resistance, reducing the anterior and afterload of the heart, rapidly improving cardiac function, and correcting heart failure. Clinical trials have shown that oplinone hydrochloride can increase cardiac output without increasing myocardial oxygen consumption, and is more effective than catecholamine preparations in improving myocardial energy. It has been reported that milrinone often has side effects such as arrhythmias and hypotension . There are no clinical studies of oplinone on blood pressure, heart rhythm, hemodynamics in China. From March 2007 to February 2009, 12 patients with chronic heart failure were treated with oplinone hydrochloride injection, closely observed the changes of clinical symptoms and signs after medication, and carried out hemodynamic monitoring before and after treatment, and achieved good treatment results.

Package

5.00kg/bag/drum, 5.00kg/bag, 2 bags/drum or according to customer’s requirements.